| You are here: Home: BCU 7|2004: D Craig Allred, MD
Select Publications
Allred D et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: Findings from NSABP Protocol B-24. Breast Cancer Res Treat 2002;Abstract 30.
Bubis JA et al. HER-2/neu overexpression: Immunohistochemistry (IHC) or fluorescence in-situ hybridization (FISH)? SABCS 2003; Poster 602. No abstract available
Dowsett M, on behalf of the ATAC Trialists’ Group. Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003;82(Suppl 1);Abstract 4.
Fisher B et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353(9169):1993-2000. Abstract
Paik S et al. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients — NSABP studies B-20 and B-14. Breast Cancer Res Treat 2003;82(Suppl 1):10;Abstract 16.
Perez EA et al. HER2 testing in patients with breast cancer: Poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 2002;77(2):148-54. Abstract
Rugo HS et al. Low to moderate protein expression of HER2/neu in breast cancer by immunohistochemistry (IHC) correlateswith low level ERBB2 gene amplification by fluorescence in situ hybridization (FISH). SABCS 2003; Poster 668. No abstract available
|
